vs
Healthpeak Properties（DOC）与怡安集团（RYAN）财务数据对比。点击上方公司名可切换其他公司
怡安集团的季度营收约是Healthpeak Properties的1.1倍（$795.2M vs $719.4M），Healthpeak Properties净利率更高（73.2% vs 5.1%，领先68.1%），怡安集团同比增速更快（15.2% vs 3.1%），过去两年Healthpeak Properties的营收复合增速更高（8.9% vs 8.1%）
Healthpeak Properties是美国医疗地产领域的房地产投资信托基金，核心投资范畴覆盖老年住宅、生命科学相关物业及医疗办公楼三类资产。公司2007年于马里兰州组建，总部设在科罗拉多州丹佛市，在尔湾、纳什维尔、旧金山均设有办事处，截至2019年12月31日共持有617处物业的权益。
怡安集团是一家业务横跨英美两国的专业服务企业，目前主要开展两大板块业务：风险资本板块提供风险管理、保险及再保险领域的经纪与咨询服务；人力资本板块则提供健康保险、退休计划、养老金计划与人才咨询相关服务。
DOC vs RYAN — 直观对比
营收规模更大
RYAN
是对方的1.1倍
$719.4M
营收增速更快
RYAN
高出12.2%
3.1%
净利率更高
DOC
高出68.1%
5.1%
两年增速更快
DOC
近两年复合增速
8.1%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $719.4M | $795.2M |
| 净利润 | $114.0M | $40.6M |
| 毛利率 | — | — |
| 营业利润率 | 17.4% | 11.9% |
| 净利率 | 73.2% | 5.1% |
| 营收同比 | 3.1% | 15.2% |
| 净利润同比 | 2406.4% | 1025.0% |
| 每股收益（稀释后） | $0.16 | $0.13 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DOCRYAN
| Q1 26 | — | $795.2M | ||
| Q4 25 | $719.4M | $738.0M | ||
| Q3 25 | $705.9M | $739.6M | ||
| Q2 25 | $694.3M | $840.9M | ||
| Q1 25 | $702.9M | $676.1M | ||
| Q4 24 | $698.0M | $649.4M | ||
| Q3 24 | $700.4M | $588.1M | ||
| Q2 24 | $695.5M | $680.2M |
净利润DOCRYAN
| Q1 26 | — | $40.6M | ||
| Q4 25 | $114.0M | $8.0M | ||
| Q3 25 | $-117.1M | $31.1M | ||
| Q2 25 | $31.7M | $52.0M | ||
| Q1 25 | $42.8M | $-27.6M | ||
| Q4 24 | $4.5M | $13.8M | ||
| Q3 24 | $85.9M | $17.6M | ||
| Q2 24 | $146.0M | $46.8M |
毛利率DOCRYAN
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 58.6% | — | ||
| Q2 25 | 60.2% | — | ||
| Q1 25 | 61.1% | — | ||
| Q4 24 | 60.3% | — | ||
| Q3 24 | 60.0% | — | ||
| Q2 24 | 60.6% | — |
营业利润率DOCRYAN
| Q1 26 | — | 11.9% | ||
| Q4 25 | 17.4% | 12.4% | ||
| Q3 25 | 9.2% | 15.0% | ||
| Q2 25 | 5.7% | 22.7% | ||
| Q1 25 | 7.7% | 14.8% | ||
| Q4 24 | -2.2% | 16.8% | ||
| Q3 24 | 14.1% | 13.9% | ||
| Q2 24 | 22.3% | 24.2% |
净利率DOCRYAN
| Q1 26 | — | 5.1% | ||
| Q4 25 | 73.2% | 1.1% | ||
| Q3 25 | -16.6% | 4.2% | ||
| Q2 25 | 4.6% | 6.2% | ||
| Q1 25 | 6.1% | -4.1% | ||
| Q4 24 | 0.7% | 2.1% | ||
| Q3 24 | 12.3% | 3.0% | ||
| Q2 24 | 21.0% | 6.9% |
每股收益（稀释后）DOCRYAN
| Q1 26 | — | $0.13 | ||
| Q4 25 | $0.16 | — | ||
| Q3 25 | $-0.17 | — | ||
| Q2 25 | $0.05 | — | ||
| Q1 25 | $0.06 | — | ||
| Q4 24 | $0.02 | — | ||
| Q3 24 | $0.12 | — | ||
| Q2 24 | $0.21 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $467.5M | $154.7M |
| 总债务越低越好 | $9.8B | $3.5B |
| 股东权益账面价值 | $7.5B | $1.2B |
| 总资产 | $20.3B | $11.0B |
| 负债/权益比越低杠杆越低 | 1.31× | 2.90× |
8季度趋势，按日历期对齐
现金及短期投资DOCRYAN
| Q1 26 | — | $154.7M | ||
| Q4 25 | $467.5M | $158.3M | ||
| Q3 25 | $91.0M | $153.5M | ||
| Q2 25 | $89.4M | $172.6M | ||
| Q1 25 | $70.6M | $203.5M | ||
| Q4 24 | $119.8M | $540.2M | ||
| Q3 24 | $180.4M | $235.2M | ||
| Q2 24 | $106.9M | $1.7B |
总债务DOCRYAN
| Q1 26 | — | $3.5B | ||
| Q4 25 | $9.8B | $3.3B | ||
| Q3 25 | $9.1B | — | ||
| Q2 25 | $9.0B | — | ||
| Q1 25 | $8.9B | — | ||
| Q4 24 | $8.7B | $3.3B | ||
| Q3 24 | $8.6B | — | ||
| Q2 24 | $8.6B | — |
股东权益DOCRYAN
| Q1 26 | — | $1.2B | ||
| Q4 25 | $7.5B | $648.1M | ||
| Q3 25 | $7.6B | $630.5M | ||
| Q2 25 | $7.9B | $610.1M | ||
| Q1 25 | $8.2B | $542.5M | ||
| Q4 24 | $8.4B | $627.7M | ||
| Q3 24 | $8.6B | $632.8M | ||
| Q2 24 | $8.8B | $605.9M |
总资产DOCRYAN
| Q1 26 | — | $11.0B | ||
| Q4 25 | $20.3B | $10.6B | ||
| Q3 25 | $19.6B | $9.9B | ||
| Q2 25 | $19.8B | $10.6B | ||
| Q1 25 | $19.8B | $9.9B | ||
| Q4 24 | $19.9B | $9.6B | ||
| Q3 24 | $20.0B | $8.5B | ||
| Q2 24 | $20.2B | $8.3B |
负债/权益比DOCRYAN
| Q1 26 | — | 2.90× | ||
| Q4 25 | 1.31× | 5.16× | ||
| Q3 25 | 1.20× | — | ||
| Q2 25 | 1.14× | — | ||
| Q1 25 | 1.08× | — | ||
| Q4 24 | 1.04× | 5.22× | ||
| Q3 24 | 1.00× | — | ||
| Q2 24 | 0.98× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $1.3B | — |
| 自由现金流经营现金流 - 资本支出 | $357.0M | — |
| 自由现金流率自由现金流/营收 | 49.6% | — |
| 资本支出强度资本支出/营收 | 124.4% | 1.7% |
| 现金转化率经营现金流/净利润 | 10.99× | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流DOCRYAN
| Q1 26 | — | — | ||
| Q4 25 | $1.3B | $263.2M | ||
| Q3 25 | $315.0M | $169.7M | ||
| Q2 25 | $363.5M | $353.6M | ||
| Q1 25 | $279.4M | $-142.8M | ||
| Q4 24 | $1.1B | $259.6M | ||
| Q3 24 | $318.2M | $100.9M | ||
| Q2 24 | $316.2M | $270.8M |
自由现金流DOCRYAN
| Q1 26 | — | — | ||
| Q4 25 | $357.0M | — | ||
| Q3 25 | — | $167.3M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $-143.5M | ||
| Q4 24 | $333.7M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
自由现金流率DOCRYAN
| Q1 26 | — | — | ||
| Q4 25 | 49.6% | — | ||
| Q3 25 | — | 22.6% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -21.2% | ||
| Q4 24 | 47.8% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
资本支出强度DOCRYAN
| Q1 26 | — | 1.7% | ||
| Q4 25 | 124.4% | 0.0% | ||
| Q3 25 | — | 0.3% | ||
| Q2 25 | — | 0.0% | ||
| Q1 25 | — | 0.1% | ||
| Q4 24 | 105.6% | 0.0% | ||
| Q3 24 | — | 0.0% | ||
| Q2 24 | — | 0.0% |
现金转化率DOCRYAN
| Q1 26 | — | — | ||
| Q4 25 | 10.99× | 32.99× | ||
| Q3 25 | — | 5.46× | ||
| Q2 25 | 11.48× | 6.80× | ||
| Q1 25 | 6.52× | — | ||
| Q4 24 | 235.43× | 18.88× | ||
| Q3 24 | 3.71× | 5.74× | ||
| Q2 24 | 2.17× | 5.79× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DOC
暂无分部数据
RYAN
| Compensation and benefits | $495.2M | 62% |
| Other | $260.4M | 33% |
| Change in contingent consideration | $27.3M | 3% |
| Fiduciary investment income | $12.3M | 2% |
